阿托伐他汀治疗脑梗死合并颈动脉粥样硬化斑块的临床研究

Clinical Efficacy of Atorvastatin for Patients with Cerebral Infarction Complicating Carotid Atherosclerotic Plaque

目的:研究阿托伐他汀对脑梗死患者颈动脉粥样硬化斑块的治疗作用及机制。方法:将150例脑梗死合并颈动脉粥样硬化斑块患者随机分为治疗组与对照组,治疗组在常规抗血小板聚集治疗的基础上给予阿托伐他汀20mg.d-1,对照组仅给予常规抗血小板聚集治疗。比较2组颈动脉斑块积分、血脂、C反应蛋白水平变化。结果:治疗组6个月、12个月复诊时的颈动脉斑块积分显著小于对照组(P<0.05),3个月后血脂水平显著下降,6个月后C反应蛋白水平明显下降。结论:阿托伐他汀可显著稳定动脉粥样硬化斑块,促进斑块消失,降低血脂。

OBJECTIVE： To study the therapeutic efficacy of atorvastatin for patients with carotid atherosclerotic plaques complicating cerebral infarction and the possible mechanism. METHODS： A total of 150 patients with cerebral infarction co- existing carotid atheroselerotic plaques were randomized to either control group （routine therapy against platelet aggregation） or trial group （routine therapy against platelet aggregation plus atorvastatin 20 mg ~ d 1）. The scores of carotid atherosclerotic plaques, levels of blood lipid and C-reactive proteins （CRP） were compared between the two groups. RESULTS： At 6 and 12 months of follow- up, the scores of carotid atherosclerotic plaques in the trial group were significantly less than in the control group（P〈0.05）, and in the trial group, the level of blood lipid at 3 months and the level of C- reactive proteins at 6 month were reduced markedly. CONCLUSION： Atorvastatin can markedly delay the progress of carotid atherosclerotic plaques and promote the elimination of carotid atherosclerotic plaques and lower blood -lipid level.